Overview

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malign

Status:
RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Based on the interaction between radiation therapy and immunotherapy and the potential potentiation of Probio-M9 for the treatment of ICIs, this study is planned to design an integrated treatment protocol for the first-line treatment of advanced gastrointestinal tumors through the use of macrofractionated radiotherapy as a means of immune activation, combined with the synergistic effect of Probio-M9 microbial agents and PD-1 inhibitors.
Phase:
NA
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Treatments:
Capecitabine
Cisplatin
Gemcitabine
Oxaliplatin
spartalizumab